New Key Statistics Module, Z-Score and F-Score
NAS:SYRS Key Ratios
| Market Cap $ M | 5.44 |
| Enterprise Value $ M | 7.39 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | -- |
| Price/Sales | 15.61 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -3.07 |
| Beneish M-Score | -7.91 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 23.10 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -0.08 |
| EV-to-EBITDA | -0.08 |
| PEG | -- |
| Shares Outstanding M | 26.83 |
| Net Margin (%) | -25,340.67 |
| Operating Margin % | -28,892.23 |
| Pre-tax Margin (%) | -25,340.67 |
| Quick Ratio | 2.25 |
| Current Ratio | 2.25 |
| ROA % (ttm) | -76.13 |
| ROE % (ttm) | -967.58 |
| ROIC % (ttm) | -324.04 |
| Dividend Yield % | -- |
| Altman Z-Score | -15.51 |
SYRS Number of Guru Trades
SYRS Volume of Guru Trades
Gurus Latest Trades with NAS:SYRS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:SYRS is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Syros Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:SYRS
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers